Combination Chemotherapy with or without Panitumumab in Treating Patients with Colorectal Cancer with Liver Metastases Previously Treated with Surgery

Inclusion Criteria

• History of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinical or radiographic evidence of extrahepatic disease; confirmation of diagnosis must be performed at Memorial Sloan Kettering Cancer Center (MSKCC)
• Completely resected hepatic metastases without current evidence of other metastatic disease
• White blood cell (WBC) >= 3.0 K/uL (=< 14 days prior to treatment start)
• Absolute neutrophil count (ANC) > 1.5 K/uL (=< 14 days prior to treatment start)
• Platelets >= 100,000/uL (=< 14 days prior to treatment start)
• Creatinine < 1.5 mg/dL (=< 14 days prior to treatment start)
• Hemoglobin (HGB) >= 9 gm/dL (=< 14 days prior to treatment start)
• Creatinine =< 1.5 mg/dL or creatinine clearance >= 50 mL/min calculated by the Cockcroft-Gault method (=< 14 days prior to treatment start)
• Aspartate aminotransferase (AST) =< 5 x upper limit of normal (ULN) and alanine aminotransferase (ALT) =< 5 x ULN (=< 14 days prior to treatment start)
• Total bilirubin =< 1.5 mg/dl (=< 14 days prior to treatment start)
• Magnesium >= lower limit of normal (=< 48 hours prior to treatment start)
• Calcium >= lower limit of normal (=< 48 hours prior to treatment start)
• Prior chemotherapy is acceptable if last dose given >= 3 weeks prior to registration to this study; (Note: no chemotherapy to be given after resection of liver lesions prior to treatment on this study)
• Any investigational agent is acceptable if administered >= 30 days before registration
• Karnofsky performance score (KPS) >= 60% (Eastern Cooperative Oncology Group [ECOG] [or Karnofsky] performance status [preferably 0 or 1/>= 60% for Karnofsky])
• Histologically confirmed all-rat sarcoma viral oncogene homolog (RAS) wild type; paraffin-embedded tumor tissue obtained from the primary tumor or metastasis (prior to)

Exclusion Criteria

• Prior radiation to the liver (prior radiation therapy to the pelvis is acceptable if completed at least 4 weeks prior to registration)
• Active infection, ascites, hepatic encephalopathy
• Prior treatment with HAI floxuridine (FUDR)
• Patients who have had prior anti-epidermal growth factor receptor (EGFR) antibody therapy and who have not responded to this treatment will be excluded; however, patients who have responded to prior anti-EGFR therapy are eligible
• Female patients who are pregnant or lactating- or planning to become pregnant within 6 months after the end of the treatment (female patients of child-bearing potential must have negative pregnancy test =< 72 hours before registration)
• If a patient has any serious medical problems which may preclude receiving this type of treatment
• Patients with current evidence of hepatitis A, B, or C (i.e., active hepatitis)
• Patients with history or known presence of primary central nervous system (CNS) tumors, seizures not well-controlled with standard medical therapy, or history of stroke will also be excluded
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to panitumumab
• Serious or non-healing active wound, ulcer, or bone fracture
• History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest computed tomography (CT) scan
• Patients who have a diagnosis of Gilbert's disease
• History of other malignancy, except: * Malignancy treated with curative intent and with no known active disease present for >= 3 years prior to registration and felt to be at low risk for recurrence by the treating physician * Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease * Adequately treated cervical carcinoma in situ without evidence of disease